Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
A Open-Label Phase in Participants With Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
GMMG-HD11/DSMM XXI/64007957MMY3010
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- Status
- RECRUITING
- Phase
- N/A
CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
- Status
- RECRUITING
- Phase
- PHASE3
Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
- Status
- RECRUITING
- Phase
- PHASE2
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
- Status
- RECRUITING
- Phase
- PHASE2
AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
- Status
- RECRUITING
- Phase
- PHASE3
QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
- Status
- RECRUITING
- Phase
- PHASE2